FDA approves launch of antiviral therapy Dovato developed by ViiV Healthcare
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
1.1 million people in the United States are currently infected with HIV, 15 percent of whom do not know they are infectedAntiviral "cocktail therapy" can effectively reduce the number of HIV viruses in the blood, prevent disease progression, and make life morehealthy(http://today, the u.SFDA(http:// announcedthe approval of The antiviral therapy Dovato and lamivudine, developed by the(http://of ViiV Healthcare, as a complete treatment for HIV-infected patients who have never received antiviral therapyAbout Dovato Health
Dovato is a compound tablet developed by ViiV in a fixed dose of dolutegravir and lamivudineDolutegravir (DTG) is a new generation of HIV-integrated enzyme inhibitorsDovato has the advantage of not only excellent antiviral efficacy, but also good safety and tolerance, and less chance of interacting with otherdrug(http://Lamivudine is a nucleoside reverse transcriptase inhibitorDovato's efficacy and safety were demonstrated in two randomized double-blindnesss in two clinically-based trials with a total of 1,433 people living with HIV,(http://) in clinicalresults showed that the combination therapy consisting of two drugs, DTG and lamivudine, had a similar effect in reducing the number of HIV viruses in the blood compared to the combination therapy consisting of dTG, emtricitabine, and tenofovir
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
